Disclaimer

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arisen from or in reliance upon the whole or any part of the contents of this announcement.

nowsoever arisen from or in reliance upon the whole or any part of the contents of this announcement.			
Cash Dividend Announcement for Equity Issuer			
Issuer name	Sisram Medical Ltd		
Stock code	01696		
Multi-counter stock code and currency	Not applicable		
Other related stock code(s) and name(s)	Not applicable		
Title of announcement	(UPDATED) FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2023		
Announcement date	08 August 2024		
Status	Update to previous announcement		
Reason for the update / change	Update on the record date and withholding tax rate		
Information relating to the dividend			
Dividend type	Final		
Dividend nature	Ordinary		
For the financial year end	31 December 2023		
Reporting period end for the dividend declared	31 December 2023		
Dividend declared	HKD 0.158 per share		
Date of shareholders' approval	Not applicable		
Information relating to Hong Kong share register			
Default currency and amount in which the dividend will be paid	HKD 0.158 per share		
Exchange rate	HKD 1 : HKD 1		
Ex-dividend date	26 August 2024		
Latest time to lodge transfer documents for registration with share registrar for determining entitlement to the dividend	27 August 2024 16:30		
Book close period	Not applicable		
Record date	27 August 2024		
Payment date	09 September 2024		
Share registrar and its address	Computershare Hong Kong Investor Services Limited		
	Shops 1712-1716		
	17th Floor		
	Hopewell Centre		
	183 Queen's Road East		
	Wanchai		

Page 1 of 2 v 1.1.1

Hong Kong

Information relating to withholding tax

Pursuant to Israeli Tax Ordinance, and based on the tax regime which applies to the Company, Shareholders are subject to a withholding tax of 20% on the 2023 Final Dividend. Such tax on the 2023 Final Dividend will be withheld at source by the Company, unless a Shareholder applies to the Israel Tax Authority and obtains an approval that it is entitled to a reduced tax rate under an applicable tax treaty between Israel and the Shareholder's country of residence.

A Shareholder who is entitled to a reduced tax rate under an applicable tax treaty between Israel and the Shareholder's country of residence, but had not obtained an approval from the Israel Tax Authority prior to a payment of a dividend, may apply for a tax refund by submitting a tax report to the Israel Tax Authority (Form 1301 for individuals and Form 1214 for companies) together with the relevant documents, such as identity document, tax residency document, certificate of incorporation and confirmation of the taxes withheld. The Company will apply to the Israeli Tax Authority for such confirmation of the taxes withheld after the payment of the 2023 Final Dividend. Shareholders can contact the Company to obtain a copy of such confirmation through various communication channels shown on the official website of the Company at www.sisram-medical.com. In the tax report, the Shareholder is required to report all his income originating in Israel (and if such Shareholder is an Israeli tax resident, he is required to report all worldwide income as well). The forms and details of how to apply for a tax refund can be obtained from the website of the Israel Tax Authority at www.taxes.gov.il. The application for a tax refund may be submitted to the Israel Tax Authority for a period of six years from the end of the year in which such dividend was distributed.

Details of withholding tax applied to the dividend declared

With respect to Shareholders who are resident in Hong Kong, there is currently no tax treaty between Israel and Hong Kong that gives rise to any tax benefits on the receipt of 2023 Final Dividend from the Company.

Type of shareholders	Tax rate	Other relevant information (if any)
All Shareholders	20%	

Information relating to listed warrants / convertible securities issued by the issuer

Details of listed warrants / convertible securities issued by the issuer

Not applicable

Other information

Other information

Not applicable

Directors of the issuer

The Board comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as executive directors; Mr. Yifang WU and Ms. Rongli FENG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

Page 2 of 2 v 1.1.1